Wealthfront Advisers LLC Has $14.76 Million Holdings in Pfizer Inc. $PFE

Wealthfront Advisers LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 6.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 579,364 shares of the biopharmaceutical company’s stock after selling 40,087 shares during the period. Wealthfront Advisers LLC’s holdings in Pfizer were worth $14,762,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the third quarter worth $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer during the second quarter worth $30,000. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer in the 2nd quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Stock Performance

PFE opened at $27.61 on Wednesday. The business’s 50-day simple moving average is $25.70 and its 200 day simple moving average is $25.13. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.73. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $156.98 billion, a PE ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. The business’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.